Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa PR Newswire Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical re...
The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis PR Newswire Two articles report results from the Phase 3 BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab, an investigational, selective inhibitor of IL-17A and IL-17F, in patient...
UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care PR Newswire 21 scientific presentations, including 7 late breakers, showcase the breadth of UCB's portfolio, reinforcing commitment ...
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS) PR Newswire Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA ® in LGS p...
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients PR Newswire New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized my...
Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis PR Newswire New late-breaking 52-week data from Phase 3 bimekizumab investigational studies ...
UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 PR Newswire Late-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondy...
UCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS PR Newswire UCB's Atlanta Warehouse is the first dually certified WELL Platinum and LEED Gold pharmaceutical project in the world and the first WELL Platinum building in G...
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting PR Newswire Results presented across UCB's generalized myasthenia gravis (gMG) development program builds the body of evidence around the complexities of gMG Presentations to inc...
New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis PR Newswire Three-year data from the BE BRIGHT open-label extension study are being presented at the 31st EADV Congress Over eight out ...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...